Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leritrelvir tablets for hospitalized mild to severe COVID-19
ChiCTR2300072062Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing Leritrelvir tablets with Placebo tablets (2 arms). Primary endpoint: Incidence of disease progression. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
leritrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300072062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072062.